Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Lenalidomide + Rituximab + Tafasitamab-cxix|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Lenalidomide||Revlimid||IMiD-1||Revlimid (lenalidomide) is a thalidomide analog which regulates cytokine production and stimulates T cells and NK cells activity (PMID: 24328678). Revlimid (lenalidomide) is FDA approved for use in multiple myeloma, relapsed or refractory Mantle cell lymphoma, and in combination with a rituximab product in follicular lymphoma and marginal zone lymphoma (FDA.gov).|
|Rituximab||Rituxan||IDEC-C2B8|MabThera||CD20 Antibody 17||Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia, and in combination with chemotherapy in pediatric patients (6 month to 18 years of age) with treatment-naive, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia (B-AL) (FDA.gov).|
|Tafasitamab-cxix||Monjuvi||MOR00208|XmAb5574|MOR-208|MOR208|Tafasitamab||CD19 Antibody 15||Monjuvi (tafasitamab-cxix) is an CD19-targeted antibody with an engineered Fc region, which may result in an increased antibody-dependent cell-mediated cytotoxicity response against CD19-expressing tumor cells (PMID: 23277329, PMID: 32511983). Monjuvi (tafasitamab-cxix) is FDA approved for use in combination with Revlimid (lenalidomide) in patients with relapsed or refractory diffuse large B cell lymphoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04680052||Phase III||Lenalidomide + Rituximab Lenalidomide + Rituximab + Tafasitamab-cxix||A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)||Recruiting||USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT||20|
|NCT04974216||Phase II||Lenalidomide + Rituximab + Tafasitamab-cxix||Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older||Recruiting||FRA | BEL||0|